Upper urinary tract surgery and radical prostatectomy with Senhance^® robotic system: Single center experience—First 100 cases

Abstract

Background The Senhance® robotic surgery system is a novel robotic platform used in several European and World centres. We present our experience in urologic surgery using this platform. Patients and Methods From May 2019 to December 2020, we performed 30 operations of upper urinary tract (UUT) and 70 extraperitoneal radical robotic prostatectomies (RRP). Relevant data were prospectively collected for key outcomes. Results The median age for UUT was 51, and for RRP 65 years. The average estimated blood loss for UUT was 30, and for RRP 200 ml. The average operating time for UUT was 160, and for RRP 200 min. In‐hospital stay for UUT was on average 4, and for RRP 5 days. In UUT group, one patient had Clavien–Dindo complication grade II and one had IIIb. In RRP, three patients had grade I complications and three patients had grade II complications. Catheter was removed on average 8 days after RRP. Conclusion The Senhance® robotic system is a safe and feasible approach to urological surge.

Letter to the editor on "Initial experience of laparoscopic radical nephrectomy using the Senhance® robotic system for renal cell carcinoma"

“…The Da Vinci is an established, wide spread, gold standard in robotic surgery, but the Senhance is more economical, as was well stated in the article [1]. We share the same opinion, although a direct comparison would be interesting [4].…”

“…We congratulate the authors for successfully treating two patients using Senhance and publishing the article. We started our Senhance robotic program in 2019 and have published two articles describing our experience [2,3] for radical prostatectomy, and very recently one including upper urinary tract surgery (UUT) [4]. There are a few points and technical details mentioned in the publication [1] we wish to comment on.…”

Senhance robot-assisted adrenalectomy: a case series

“…The Senhance Surgical System offers open platform strategy and reusable instruments, potentially becoming a more affordable option than the Da Vinci ( 15 ). There are only a few reports of successful Senhance robotic-assisted procedures in urology for both benign and malignant conditions ( 2 , 5 , 6 , 10 , 11 , 16 - 18 ). This report broadens the urologic catalog of Senhance robot-assisted procedures by adding adrenalectomy for benign adrenal tumors.…”

A Scoping Review of Emerging and Established Surgical Robotic Platforms With Applications in Urologic Surgery

“…Samalavicius and colleagues performed 31 radical prostatectomies using Senhance, with few complications and no conversion to open procedures [35]. A subsequent case series reported decreases in positive surgical margin rate and lower rates of postoperative incontinence in patients undergoing radical prostatectomy, and expanded the application of the Senhance robotic platform to adrenalectomies, nephrectomy, kidney cyst fenestration, and pyeloplasty with success [36]. The aforementioned developments and clinical data showing the success of the Senhance platform will make it a strong competitor in the field of master-slave surgical robots.…”